Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DPP4 | P27487 | 4/20 | 0.46 |
| ▸ | HTR7 | P34969 | 5/20 | 0.39 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.37 |
| ▸ | GAA | P10253 | 1/20 | 0.37 |
| ▸ | CREBBP | Q92793 | 1/20 | 0.36 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.35 |
| ▸ | SIRT5 | Q9NXA8 | 1/20 | 0.34 |
| ▸ | LRRK2 | Q5S007 | 1/20 | 0.34 |
| ▸ | MAPT | P10636 | 1/20 | 0.34 |
| ▸ | APP | P05067 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2002773 | 0.82 | DPP4 (0.43) | DPP4HTR7 | |
| SCHEMBL2001399 | 0.79 | DPP4 (0.42) | DPP4HSD17B10ALDH1A1GAAKDM4E | |
| SCHEMBL14369438 | 0.79 | DPP4 (0.47) | DPP4MAPT | |
| SCHEMBL1995242 | 0.77 | DPP4 (0.44) | DPP4 | |
| SCHEMBL5158690 | 0.70 | DPP4 (0.46) | DPP4HSD17B10ALDH1A1GAACREBBP | |
| SCHEMBL26109661 | 0.69 | CA12 (0.41) | HTR7HSD17B10ALDH1A1GAACREBBP | |
| SCHEMBL6867119 | 0.69 | TAAR1 (0.55) | DPP4HTR7HSD17B10ALDH1A1GAA | |
| SCHEMBL30597001 | 0.69 | CA12 (0.41) | HTR7HSD17B10ALDH1A1GAACREBBP | |
| SCHEMBL5325810 | 0.69 | DPP4 (0.45) | DPP4HSD17B10ALDH1A1GAACREBBP | |
| SCHEMBL3149462 | 0.67 | DPP4 (0.57) | DPP4HTR7HSD17B10ALDH1A1LRRK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7960384-B2 | Dipeptidyl peptidase inhibitors | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2011-06-14 | — | — | US | claimed |
| US-20070249611-A1 | DIPEPTIDYL PEPTIDASE INHIBITORS | TAKEDA SAN DIEGO, INC. | 2007-10-25 | — | — | US | claimed |
| WO-2007112347-A1 | DIPEPTIDYL PEPTIDASE INHIBITORS | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2007-10-04 | — | — | WO | claimed |
| US-7960384-B2 | Dipeptidyl peptidase inhibitors | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2011-06-14 | — | — | US | disclosed |
| US-7960384-B2 | Dipeptidyl peptidase inhibitors | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2011-06-14 | — | — | US | disclosed |
| US-7960384-B2 | Dipeptidyl peptidase inhibitors | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2011-06-14 | — | — | US | disclosed |
| US-20070249611-A1 | DIPEPTIDYL PEPTIDASE INHIBITORS | TAKEDA SAN DIEGO, INC. | 2007-10-25 | — | — | US | disclosed |
| US-20070249611-A1 | DIPEPTIDYL PEPTIDASE INHIBITORS | TAKEDA SAN DIEGO, INC. | 2007-10-25 | — | — | US | disclosed |
| US-20070249611-A1 | DIPEPTIDYL PEPTIDASE INHIBITORS | TAKEDA SAN DIEGO, INC. | 2007-10-25 | — | — | US | disclosed |
| WO-2007112347-A1 | DIPEPTIDYL PEPTIDASE INHIBITORS | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2007-10-04 | — | — | WO | disclosed |
| WO-2007112347-A1 | DIPEPTIDYL PEPTIDASE INHIBITORS | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2007-10-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070249611-A1 | DIPEPTIDYL PEPTIDASE INHIBITORS | DPP3, DPP4, DPP7 | DPP4 2/4885HTR7 1374/4885HSD17B10 533/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.